Stockreport

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GeneDx Holdings Corp. - Class A  (WGS) 
PDF Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new oppo [Read more]